Search

Your search keyword '"Moleti ML"' showing total 154 results
Start Over Author "Moleti ML"
154 results on '"Moleti ML"'

1. Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies

Author

Malfona F, Testi AM, Chiaretti S, and Moleti ML

Subjects
burkitt lymhoma – target therapy – relapse – refractory – outcome, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, Maria Luisa Moleti Department of Translational and Precision Medicine, ‘Sapienza’ University, Rome, ItalyCorrespondence: Maria Luisa Moleti, Hematology Institute, Via Benevento 6, Rome, 00161, Italy, Tel +39 3384714201, Fax +39 0644641984, Email moleti@bce.uniroma1.itAbstract: Despite excellent results in frontline therapy, particularly in pediatric age, refractory Burkitt lymphoma still remains a therapeutic challenge, with dismal outcome. The prognosis is very poor, ranging from less than 10% to 30– 40%, with longer survival only in transplanted patients. On account of the paucity of data, mostly reporting on small series of patients, with heterogeneous characteristics and salvage treatments, at present it is impossible to draw definitive conclusions on the treatment of choice for this difficult to treat subset of patients. New insights into Burkitt lymphoma/leukemia cell biology have led to the development of new drugs, currently being tested, directed at different specific targets. Herein, we describe the results so far reported in refractory Burkitt lymphoma/leukemia, with standard treatments and hematopoietic stem cell transplant, and we review the new targeted drugs currently under evaluation.Keywords: Burkitt lymphoma, target therapy, relapse, refractory, outcome

Published
2024

2. Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review

Author

Testi AM, Moleti ML, Angi A, Bianchi S, Barberi W, and Capria S

Subjects
autologous stem cell transplant, pediatric age, acute leukemia, chronic myeloid leukemia, hodgkin lymphoma, non-hodgkin lymphoma, Pediatrics, RJ1-570
Abstract

Anna Maria Testi, Maria Luisa Moleti, Alessia Angi, Simona Bianchi, Walter Barberi, Saveria Capria Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, ItalyCorrespondence: Anna Maria Testi, Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Via Benevento 6, Rome, 00161, Italy, Tel +39-06-49974731, Fax +39-06-44241984, Email testi@bce.uniroma1.itAbstract: Autologous stem cell transplantation (auto-HSCT) is a part of the therapeutic strategy for various oncohematological diseases. The auto-HSCT procedure enables hematological recovery after high-dose chemotherapy, otherwise not tolerable, by the infusion of autologous hematopoietic stem cells. Unlike allogeneic transplant (allo-HSCT), auto-HSCT has the advantage of lacking acute-graft-versus-host disease (GVHD) and prolonged immunosuppression, however, these advantages are counterbalanced by the absence of graft-versus-leukemia. Moreover, in hematological malignancies, the autologous hematopoietic stem cell source may be contaminated by neoplastic cells, leading to disease reappearance. In recent years, allogeneic transplant-related mortality (TRM) has progressively decreased, almost approaching auto-TRM, and many alternative donor sources are available for the majority of patients eligible for transplant procedures. In adults, the role of auto-HSCT compared to conventional chemotherapy (CT) in hematological malignancies has been well defined in many extended randomized trials; however, such trials are lacking in pediatric cohorts. Therefore, the role of auto-HSCT in pediatric oncohematology is limited, in both first- and second-line therapies and still remains to be defined. Nowadays, the accurate stratification in risk groups, according to the biological characteristics of the tumors and therapy response, and the introduction of new biological therapies, have to be taken into account in order to assign auto-HSCT a precise role in the therapeutic strategies, also considering that in the developmental age, auto-HSCT has a clear advantage over allo-HSCT, in terms of late sequelae, such as organ damage and second neoplasms. The purpose of this review is to report the results obtained with auto-HSCT in the different pediatric oncohematological diseases, focusing on the most significant literature data in the context of the various diseases and discussing this data in the light of the current therapeutic landscape.Keywords: autologous stem cell transplant, pediatric age, acute leukemia, chronic myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma

Published
2023

3. Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study

Author

Micozzi A, Minotti C, Capria S, Cartoni C, Trisolini SM, Assanto GM, Barberi W, Moleti ML, Santilli S, Martelli M, and Gentile G

Subjects
ceftazidime-avibactam, colistin, haematological malignancies, kpc-k.pneumoniae-bsi mortality rate, Infectious and parasitic diseases, RC109-216
Abstract

Alessandra Micozzi,1 Clara Minotti,2 Saveria Capria,2 Claudio Cartoni,2 Silvia Maria Trisolini,2 Giovanni Manfredi Assanto,1 Walter Barberi,2 Maria Luisa Moleti,2 Stefania Santilli,3 Maurizio Martelli,1 Giuseppe Gentile1 1Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 2Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy; 3Department of Diagnostics, Azienda Policlinico Umberto I, Rome, ItalyCorrespondence: Alessandra Micozzi, Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Via Benevento 6, Rome, 00161, Italy, Tel +39 6 857951, Fax +39 6 44241984, Email alessandra.micozzi@uniroma1.itPurpose: To evaluate the benefits and safety of the empiric antibiotic treatment (EAT) active against KPC-K. pneumoniae in febrile neutropenic patients with acute leukaemia (AL) who are colonised by KPC-K. pneumoniae.Patients and Methods: A 7-year (2013– 2019) retrospective observational cohort study was conducted at the Haematology, Sapienza Rome University (Italy) on 94 febrile neutropenia episodes (FNE) in AL patients KPC-K. pneumoniae carriers treated with active EAT.Results: Eighty-two (87%) FNE were empirically treated with antibiotic combinations [38 colistin-based and 44 ceftazidime-avibactam (CAZAVI)-based], 12 with CAZAVI monotherapy. Successful outcomes were observed in 88/94 (94%) FNE, 46/49 (94%) microbiologically documented infections, and 24/27 (89%) gram-negative bloodstream infections (GNB-BSI). Mortality due to infective causes was 4.2% (2.1% within 1 week). KPC-K. pneumoniae infections caused 28/94 FNE (30%) and KPC-K. pneumoniae-BSI was documented in 22 FNE (23.4%) (85% of GNB-BSI), in all cases patients received active EAT, and 21 survived. KPC-K.pneumoniae-BSI mortality rate was 4.5%. CAZAVI-based EAT showed better results than colistin-based EAT (55/56 vs 33/38, p = 0.037), overall and without EAT modification (41/56 vs 20/38, p = 0.02). Empirical combinations including CAZAVI were successful in 98% of cases (43/44 vs 33/38 for colistin-based EAT, p = 0.01), without modifications in 82% (36/44 vs 20/28, p = 0.02). All deaths occurred in patients treated with colistin-based EAT (4/38 vs 0/56, p = 0.02). CAZAVI-containing EAT was the only independent factor for an overall successful response (HR 0.058, CI 0.013– 1.072, p = 0.058). Nephrotoxicity occurred in 3(8%) patients undergoing colistin-based EAT (none in those undergoing CAZAVI-based EAT, p = 0.02).Conclusion: KPC-K. pneumoniae infections are frequent in colonised AL patients with FNE. EAT with active antibiotics, mainly CAZAVI-based combinations, was effective, safe, and associated with low overall and KPC-K. pneumoniae-BSI-related mortality.Keywords: ceftazidime-avibactam, colistin, haematological malignancies, KPC-K. pneumoniae-BSI mortality rate

Published
2023

9. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

Author

TESTI AM, DEL GIUDICE I, ARCESE W, MOLETI ML, GIONA F, BASSO G, BIONDI A, CONTER V, MESSINA C, RONDELLI R, MICOZZI A, MICALIZZI C, BARISONE E, LOCATELLI F, DINI G, ARICO M, COMIS M, LADOGANA S, LIPPI A, MURA R, PINTA MF, SANTORO N, VALSECCHI MG, MASERA G, MANDELLI F, AIEOP COOPERATIVE GROUP, CASALE, Fiorina, Testi, Am, DEL GIUDICE, I, Arcese, W, Moleti, Ml, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Arico, M, Casale, Fiorina, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, Mf, Santoro, N, Valsecchi, Mg, Masera, G, Mandelli, F, AIEOP COOPERATIVE, Group, Testi, A, Del Giudice, I, Moleti, M, Aricò, M, Casale, F, Pinta, M, and Valsecchi, M

Subjects
Male, Antineoplastic Combined Chemotherapy Protocol, Adolescent, Cytarabine, Hematopoietic Stem Cell Transplantation, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Disease-Free Survival, Follow-Up Studie, Survival Rate, Recurrence, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Preschool, Child, Idarubicin, Follow-Up Studies, Settore MED/15 - Malattie del Sangue, Human
Abstract

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complete remission; eight (8%) died during induction and 11 (11%) failed to respond. A total of 42 out of the 80 responders (52.5%) received a SCT: 19 from an identical sibling, 11 from a matched unrelated donor and 12 from umbilical cord blood cells. The estimated 4-year overall survival and event-free survival were 25% and 21% respectively. Disease-free survival at 4 years was 25.8% for the 80 responders. At 4 years, 39 out of 100 children remain alive, with 27 of them free of leukaemia. This induction therapy has shown antileukaemic efficacy with acceptable toxicity; moreover, all responders proved eligible for intensive consolidation.

Published
2002

20. Lymphocyte Predominant Hodgkin Lymphoma. A Multicenter Retrospective 30-Year Experience of the Italian Pediatric Hematology and Oncology Association (AIEOP)

Author

Mascarin, M, primary, Elia, C, additional, Bianchi, M, additional, Bertolini, P, additional, Buffardi, S, additional, Caniglia, M, additional, Caruso, R, additional, Cellini, M, additional, Cesaro, S, additional, Consarino, C, additional, D'Amico, S, additional, De Santis, R, additional, Farruggia, P, additional, Cecinati, V, additional, Garaventa, A, additional, Indolfi, P, additional, Moleti, ML, additional, Murgia, G, additional, Nardi, M, additional, Pierani, P, additional, Porta, F, additional, Rondelli, R, additional, Sala, A, additional, Santoro, N, additional, Todesco, A, additional, Zanazzo, GA, additional, Zecca, M, additional, and Burnelli, R, additional

Published
2014
Full Text
View/download PDF

21. Role of Interim FDG-PET for Mediastinal Response Assessment in Pediatric Hodgkin's Lymphoma (HL):Preliminary Results from the Italian AIEOP-LH2004 Protocol

Author

Burnelli, R, primary, Lopci, E, additional, Elia, C, additional, Piccardo, A, additional, Todesco, A, additional, Garaventa, A, additional, Sala, A, additional, Farruggia, P, additional, Zucchetta, P, additional, Guerra, L, additional, Indolfi, P, additional, Buffardi, S, additional, Moleti, ML, additional, Cistaro, A, additional, Fanti, S, additional, Chiti, A, additional, and Mascarin, M, additional

Published
2014
Full Text
View/download PDF

28. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

Author

Giona, F, Teofili, Luciana, Moleti, Ml, Martini, Maurizio, Palumbo, Giuseppe, Amendola, A, Mazzucconi, Mg, Testi, Am, Pignoloni, P, Orlando, Sm, Capodimonti, Sara, Nanni, Marinella, Leone, Giuseppe, Larocca, Luigi Maria, Foa', R., Teofili, Luciana (ORCID:0000-0002-7214-1561), Martini, Maurizio (ORCID:0000-0002-6260-6310), Larocca, Luigi Maria (ORCID:0000-0003-1739-4758), Giona, F, Teofili, Luciana, Moleti, Ml, Martini, Maurizio, Palumbo, Giuseppe, Amendola, A, Mazzucconi, Mg, Testi, Am, Pignoloni, P, Orlando, Sm, Capodimonti, Sara, Nanni, Marinella, Leone, Giuseppe, Larocca, Luigi Maria, Foa', R., Teofili, Luciana (ORCID:0000-0002-7214-1561), Martini, Maurizio (ORCID:0000-0002-6260-6310), and Larocca, Luigi Maria (ORCID:0000-0003-1739-4758)

Abstract

Sixty-four patients < 20 years of age, investigated for a suspicion of Philadelphia-negative myeloproliferative disease (MPD), were retrospectively evaluated to characterize the different forms and to examine the treatments used and long-term outcome. JAK2 mutations, endogenous erythroid colony growth, and clonality were investigated in 51 children. Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin receptor and mutations of other genes involved in the pathogenesis of MPD were investigated in JAK2 wild-type patients. Based on our criteria for childhood MPD, we identified 34 patients with sporadic thrombocythemia (ST), 16 with hereditary thrombocytosis (HT), 11 with sporadic polycythemia (SP), and 3 with hereditary polycythemia (HP). JAK2(V617F) mutations were present in 47.5% of ST and in no HT. The MPL(S505A) mutation was detected in 15/16 HT patients and in no ST (P < .00001). The JAK2(V617F) mutation occurred in 27% of SP patients diagnosed according to the Polycythemia Vera Study Group or World Health Organization 2001 criteria. Children with ST received more cytoreductive drugs than those with HT (P = .0006). After a median follow-up of 124 months, no patient had developed leukemia or myelofibrosis and 5% had thrombosis; the miscarriage rate in thrombocythemic patients was 14%. The low complication rate in our population suggests that children with MPD may be managed by tailored approaches.

Published
2012

32. Protocollo AIEOP LNH92 per i linfomi non Hodgkin pediatrici

Author

Pillon, M, Rosolen, Angelo, Putti, Mc, Santoro, N, D’Angelo, P, Izzi, G, Tamaro, P, Lippi, A, Cellinim, Ragusa, L, Favre, C, Arrighini, A, Moleti, Ml, Felici, L, Marcellino, C, Varotto, S, and Zanesco, Luigi

Published
1998

39. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children

Author

Testi, A, Biondi, A, Lo Coco, F, Moleti, M, Giona, F, Vignetti, M, Menna, G, Locatelli, F, Pession, A, Barisone, E, De Rossi, G, Diverio, D, Micalizzi, C, Aricò, M, Basso, G, Foa, R, Mandelli, F, Testi, AM, Moleti, ML, Mandelli, F., BIONDI, ANDREA, Testi, A, Biondi, A, Lo Coco, F, Moleti, M, Giona, F, Vignetti, M, Menna, G, Locatelli, F, Pession, A, Barisone, E, De Rossi, G, Diverio, D, Micalizzi, C, Aricò, M, Basso, G, Foa, R, Mandelli, F, Testi, AM, Moleti, ML, Mandelli, F., and BIONDI, ANDREA

Abstract

The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing studies. The results of the Italian pediatric experience with the multicentric Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA)-Italian Pediatric Hematology and Oncology Group (AIEOP) "AIDA" (ATRA and idarubicin) trial are presented. Of the 983 patients with APL enrolled in this protocol between January 1993 and June 2000, 124 (13%) had younger than 18 years. Treatment consisted of ATRA and idarubicin induction followed by 3 polychemotherapy consolidation courses. Molecular response by reverse transcriptase-polymerase chain reaction (RT-PCR) was assessed after consolidation and patients who were PCR- were randomized for different maintenances. One hundred and seven children were eligible and evaluable for induction: 103 (96%) achieved a hematologically complete remission. Overt ATRA syndrome was observed in 2 patients and pseudotumor cerebri was observed in 10 patients. Ninety-four patients were evaluable for RT-PCR analysis at the end of consolidation: 91 (97%) proved PCR+ and 3 PCR-. The overall survival and event-free survival (EFS) are 89% (95% confidence interval [c.i.]: 83%-95%) and 76% (c.i.: 65%-85%), respectively, at more than 10 years. A white blood cell (WBC) count at diagnosis of greater than 10 x 10(9)/L had a significant impact on EFS (59% vs 83% at 10 years). These results highlight the efficacy and feasibility of the AIDA protocol in the pediatric APL population.

Published
2005

41. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

Author

Testi, A, Del Giudice, I, Arcese, W, Moleti, M, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Aricò, M, Casale, F, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, M, Santoro, N, Valsecchi, M, Masera, G, Mandelli, F, Testi, AM, Moleti, ML, BIONDI, ANDREA, Pinta, MF, Mandelli, F., VALSECCHI, MARIA GRAZIA, Testi, A, Del Giudice, I, Arcese, W, Moleti, M, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Aricò, M, Casale, F, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, M, Santoro, N, Valsecchi, M, Masera, G, Mandelli, F, Testi, AM, Moleti, ML, BIONDI, ANDREA, Pinta, MF, Mandelli, F., and VALSECCHI, MARIA GRAZIA

Abstract

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complete remission; eight (8%) died during induction and 11 (11%) failed to respond. A total of 42 out of the 80 responders (52.5%) received a SCT: 19 from an identical sibling, 11 from a matched unrelated donor and 12 from umbilical cord blood cells. The estimated 4-year overall survival and event-free survival were 25% and 21% respectively. Disease-free survival at 4 years was 25.8% for the 80 responders. At 4 years, 39 out of 100 children remain alive, with 27 of them free of leukaemia. This induction therapy has shown antileukaemic efficacy with acceptable toxicity; moreover, all responders proved eligible for intensive consolidation

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results